Institute for Applied Cancer Science
To effectively impact patient care, IACS programs are selected for their ability to change the course of disease. Three elements are integral considerations for each program that becomes part of IACS’s portfolio because they are central components of clinical success:
- adequate knowledge of target biology in initiating and sustaining tumorgenesis,
- selection of proper drug properties with the appropriate characteristic to inhibit the target in patients for the required duration and that can be combined with other agents and
- identification of the appropriate patient population and the development of a preclinical data package to support this strategy.
IACS programs are the result of close collaborations with MD Anderson investigators, as well as extensive landscape analysis.
IACS conducts an extensive upfront evaluation of all potential targets, specifically considering: (1) Disease Relevance – impact on tumor development and maintenance; (2) Tractability – potential for therapeutic attack; and (3) Translatability – potential for clinical development. Potential targets are continually reviewed and this upfront robust research allows IACS to move quickly to pre-defined go/no-go experiments once a project becomes part of the portfolio. IACS looks to mature into a self-sustaining venture through careful program management.